当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

Abstract：

BACKGROUND:Current results regarding treatment outcomes in acute myeloid leukemia (AML) point to significant differences between low- and middle-income countries (LMIC) and high-income countries (HIC). Excluding well-known socioeconomic issues, genetic markers important for prognosis have not been properly incorporated into the clinical practice so far and their usefulness outside of well-controlled clinical trials remain unknown. METHODS:Here, we assessed the clinical significance of the European LeukemiaNet (ELN) recommendations in 196 consecutive patients with AML in a real-life setting. All patients were younger than 60 years of age (49% male) and treated with conventional chemotherapy for induction and consolidation in three Brazilian Institutions that well represent Brazilian geographic and socioeconomic diversity. FINDINGS:Multivariable analysis showed that ELN recommendations had a slight association with complete remission achievement (odds ratio: 0.74, 95% confidence interval, CI: 0.53-1.01; P=0.06), but were independently associated with poor overall survival (OS) (hazard ratio, HR: 1.3, 95% CI: 1.1-1.54; P=0.002), disease-free survival (DFS) (HR: 1.42, 95% CI: 1.03-1.95; P=0.028) and event-free survival (EFS) (HR: 1.24, 95% CI: 1.06-1.47; P=0.007), considering initial leukocyte counts and age as confounders. ELN recommendations had no impact on cumulative incidence of relapse (P=0.09). INTERPRETATION:Our results suggest that within the context of LMIC, the prognostic markers recommended by ELN may be useful to predict patient's clinical outcomes; however, the OS, DFS and EFS were shorter than the reported in Europe and US for the respective risk groups.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Benicio MTL,Ribeiro AFT,Américo AD,Furtado FM,Glória AB,Lima AS,Santos SM,Xavier SG,Lucena-Araujo AR,Fagundes EM,Rego EM

doi

10.1016/j.leukres.2017.07.005

subject

Has Abstract

pub_date

2017-09-01 00:00:00

pages

109-114

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(17)30470-8

journal_volume

60

pub_type

杂志文章,多中心研究

相关文献

LEUKEMIA RESEARCH文献大全
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract：:There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2020.106385

    authors： Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期：2020-08-01 00:00:00

  • Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

    abstract：:Although mutations in RNA splicing genes occur frequently in patients with clonal cytopenias of unknown significance (CCUS) and myelodysplastic syndromes (MDS), very often additional common myeloid gene driver mutations are present at diagnosis. Thus, the clinical significance of isolated mutations in the most commonl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.09.002

    authors： Fleischman RA,Stockton SS,Cogle CR

    更新日期：2017-10-01 00:00:00

  • Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.

    abstract：:In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)00118-t

    authors： van der Hem KG,Dräger AM,Odding JH,Langenhuijsen MM,Huijgens PC

    更新日期：1995-01-01 00:00:00

  • The induction kinetics of Il-8 messenger RNA in HL60 cells demonstrate the participation of negative-acting gene(s).

    abstract：:Interleukin-8 (IL-8) mRNA was rapidly, but not permanently, induced at high levels by phorbol-12myristate-13acetate (PMA) in HL60 cells. Ongoing protein synthase does not seem to be required for the initial induction of IL-8 gene expression. However, the rate of transient induction kinetics was modulated by cyclohexim...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)00151-y

    authors： Meier RW,Niklaus G,Fey MF,Tobler A

    更新日期：1995-07-01 00:00:00

  • Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement.

    abstract：:Two AML patients, whose leukemic clonogenic cells totally reacted to the anti-lactofucopentaose III S4-7 monoclonal antibody (MoAb), underwent autologous bone marrow transplantation, in first complete remission, after in-vitro purging with S4-7 MoAb and complement. After ablative chemotherapy (BAVC regimen) and reinfu...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90050-6

    authors： Ferrero D,De Fabritiis P,Amadori S,De Felice L,Gallo E,Meloni G,Pregno P,Pulsoni A,Simone F,Tarella C

    更新日期：1987-01-01 00:00:00

  • A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.

    abstract：:Anti-MY9 is an IgG2b murine monoclonal antibody selected for reactivity with immature normal human myeloid cells. The MY9 antigen is expressed by blasts, promyelocytes and myelocytes in the bone marrow, and by monocytes in the peripheral blood. Erythrocytes, lymphocytes and platelets are MY9 negative. All myeloid colo...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90001-8

    authors： Griffin JD,Linch D,Sabbath K,Larcom P,Schlossman SF

    更新日期：1984-01-01 00:00:00

  • Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.

    abstract：:The WHO classification of hematological malignancies includes 5q-syndrome as a separate category within myelodysplastic syndromes (MDS). Clinically, patients with 5q-syndrome have a milder disease than patients with other MDS. The basis for this difference is not known. Identifying 5q-syndrome can be difficult because...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00039-5

    authors： Washington LT,Jilani I,Estey E,Albitar M

    更新日期：2002-10-01 00:00:00

  • Synergistic effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line.

    abstract：:We investigated the accumulation of DNA strand breaks in a human promyelocytic leukemia cell line, HL-60, treated with methotrexate (MTX) and 1-beta-D-arabinofuranosylcytosine (Ara-C). The sequential treatment with MTX then Ara-C had a synergistic effect on the formation of DNA strand breaks, which was dependent on MT...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90139-2

    authors： Tanizawa A,Kubota M,Takimoto T,Kito T,Akiyama Y,Kiriyama Y,Mikawa H

    更新日期：1989-01-01 00:00:00

  • The clinical relevance of IgG subclasses in acute leukemias: low serum IgG as a risk factor for early death due to infection in acute myelogenous leukemia.

    abstract：:In order to investigate the clinical significance of IgG subclass levels in adult patients treated for acute lymphocytic (ALL) or myelogenous leukemias (AML), patients were tested before and in regular intervals during and after chemotherapy. Ten patients treated for acute lymphocytic leukemia had normal total IgG and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(92)90128-t

    authors： Gause A,Schmitz G,von Kalle AK,Lathan B,Diehl V,Pfreundschuh M

    更新日期：1992-01-01 00:00:00

  • A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naïve T cells.

    abstract：:We established a plasmacytoid dendritic cell (pDC) line (PMDC05) from leukemia cells of pDC leukemia. PMDC05 cells were positive for CD4, CD56, CD33, HLA-DR, CD123 (IL-3Ralpha) and CD86 in the absence of lineage markers. mRNA of TLR1, TLR2, TLR4, TLR7 and TLR9 was clearly expressed and among these TLRs, TLR7 was promi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.047

    authors： Narita M,Watanabe N,Yamahira A,Hashimoto S,Tochiki N,Saitoh A,Kaji M,Nakamura T,Furukawa T,Toba K,Fuse I,Aizawa Y,Takahashi M

    更新日期：2009-09-01 00:00:00

  • Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.

    abstract：:We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.04.025

    authors： Klimek VM,Dolezal EK,Tees MT,Devlin SM,Stein K,Romero A,Nimer SD

    更新日期：2012-09-01 00:00:00

  • Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

    abstract：:We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2013.05.007

    authors： Altman JK,Rademaker A,Cull E,Weitner BB,Ofran Y,Rosenblat TL,Haidau A,Park JH,Ram SL,Orsini JM Jr,Sandhu S,Catchatourian R,Trifilio SM,Adel NG,Frankfurt O,Stein EM,Mallios G,Deblasio T,Jurcic JG,Nimer S,Peterson L

    更新日期：2013-09-01 00:00:00

  • Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

    abstract：:We compared the growth-inhibitory effects and inhibition profile of the SRC family kinases (SFKs) of imatinib, dasatinib, nilotinib and INNO-406. Dasatinib exhibited the strongest potency against BCR-ABL with little selectivity over SFKs. Nilotinib exhibited a weaker affinity than the other inhibitors, but was highly ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.008

    authors： Deguchi Y,Kimura S,Ashihara E,Niwa T,Hodohara K,Fujiyama Y,Maekawa T

    更新日期：2008-06-01 00:00:00

  • Using haplotype analysis to elucidate significant associations between genes and Hodgkin lymphoma.

    abstract：:In this study, we estimated the association between the inferred haplotypes in the inflammation, DNA repair, and folate pathways, and developed risk models for Hodgkin lymphoma. The study population consisted of 200 Hodgkin lymphoma cases and 220 controls. A susceptible association was observed on the XPC gene with ha...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.07.014

    authors： D'Amelio AM Jr,Monroy C,El-Zein R,Etzel CJ

    更新日期：2012-11-01 00:00:00

  • Parameters involved in the recognition of fresh human leukemic blasts by tumor-specific cytolytic T cell clones: a model study.

    abstract：:Although clinical experience and in vitro data provide evidence of an anti-leukemic activity of T cells, there are few examples of recognition of leukemic cells by tumor-specific T cells in vitro. Tumor antigens encoded by the MAGE genes are useful tools to study this recognition. We tested the sensitivity to recognit...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(00)00053-9

    authors： Chambost H,Collette Y,Dutartre H,Thuret I,Olive D

    更新日期：2000-10-01 00:00:00

  • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.

    abstract：:The Bcl-2 protein inhibits apoptosis (programmed cell death) of hematopoietic stem cells induced by a variety of noxious stimuli, thus mediating chemoresistance and decreasing chemosensitivity. Higher Bcl-2 expression correlates to an adverse outcome following therapy for acute myeloid leukemia (AML). The current stud...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.05.009

    authors： Moon JH,Sohn SK,Lee MH,Jang JH,Kim K,Jung CW,Kim DH

    更新日期：2010-02-01 00:00:00

  • Flow cytometric assessment of three different methods for the measurement of in vitro apoptosis.

    abstract：:Chlorambucil-induced apoptosis was assessed by three different flow cytometric methods in B-cell chronic lymphocytic leukaemia (B-CLL) cells cultured in vitro and the results were compared with those derived from the morphological assessment of the same samples. Spontaneous apoptosis was consistently observed in the c...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00013-7

    authors： Pepper C,Thomas A,Tucker H,Hoy T,Bentley P

    更新日期：1998-05-01 00:00:00

  • Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

    abstract：:Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) patients and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 patients to the 89 cases from the...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2010.07.031

    authors： Noor SJ,Tan W,Wilding GE,Ford LA,Barcos M,Sait SN,Block AW,Thompson JE,Wang ES,Wetzler M

    更新日期：2011-05-01 00:00:00

  • The incidence of hybrid acute leukaemias.

    abstract：:During a 4-yr period, 292 patients with acute leukaemia were studied using morphology, cytochemistry and immunologic reagents to determine the cell lineage of the leukaemia. One hundred and sixty-three cases were shown to be acute lymphoblastic leukaemia (ALL), 127 acute myeloblastic leukaemia (AML) and two cases (0.6...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(88)90002-1

    authors： Ruiz-Argüelles GJ,Lobato-Mendizábal E,Marín-López A

    更新日期：1988-01-01 00:00:00

  • Bone marrow pre-B expansion by SL/Kh-Bomb1 locus: not sufficient for lymphomagenesis.

    abstract：:The pre-B lymphoma in SL/Kh mice is a polygenic trait involving a number of host genes. In prelymphoma-stage bone marrow, transient pre-B cell expansion is induced by a host locus, Bomb1, and later followed by the emergence of a monoclonal population with a similar phenotype. To determine whether these pre-B cells rep...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.05.013

    authors： Hiratsuka T,Tsuruyama T,Kaszynski R,Kometani K,Minato N,Nakamura T,Tamaki K,Hiai H

    更新日期：2008-02-01 00:00:00

  • Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.

    abstract：:To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate ± 6-mercaptopurine in maintenance treatment ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.03.027

    authors： Huang H,Qin Y,Xu R,You X,Teng R,Yang L,Xu M,Liu H

    更新日期：2012-07-01 00:00:00

  • Gene mutations in myelodysplasia.

    abstract：:The myelodysplastic syndrome is a paradigm of human preleukaemia. Normal haemopoiesis is progressively displaced by an abnormal clone derived from a mutated stem cell. The initial mutation is unknown but its occurrence may be related to the overall load of random mutations which are a consequence of both intrinsic DNA...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(92)90099-s

    authors： Jacobs A

    更新日期：1992-01-01 00:00:00

  • Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature.

    abstract：:The aim of this study is to detect the biologic and/or prognostic significance of survivin (S) and effector protease receptor 1: EPR-1 (E) expression in acute leukemias (34 ALL and 40 AML) by using RT-PCR. S and E expressions were found in 83.8 and 20.3% of the cases, respectively. S was detected in 90%, 76.5% and E w...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.01.005

    authors： Oto OA,Paydas S,Tanriverdi K,Seydaoglu G,Yavuz S,Disel U

    更新日期：2007-11-01 00:00:00

  • Iron chelators induce autophagic cell death in multiple myeloma cells.

    abstract：:We examined the antineoplastic effects of the iron chelators, deferasirox and deferoxamine in multiple myeloma cell lines as well as primary myeloma cells. These iron chelators showed marked antiproliferative activity as well as cytotoxicity toward myeloma cell lines and deferasirox was cytotoxic to bone marrow plasma...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.06.005

    authors： Pullarkat V,Meng Z,Donohue C,Yamamoto VN,Tomassetti S,Bhatia R,Krishnan A,Forman SJ,Synold TW

    更新日期：2014-08-01 00:00:00

  • Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid.

    abstract：:All-trans-retinoic acid (ATRA) has been proven active against a range of malignancies in isolated tissue culture systems and in human clinical trials, but the duration of its effects has been transient. Recent evidence indicates that the basis for the limited duration of ATRA's activity, at least in one form of leukem...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)90040-x

    authors： Mehta K,Sadeghi T,McQueen T,Lopez-Berestein G

    更新日期：1994-08-01 00:00:00

  • Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

    abstract：:Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2017.01.033

    authors： Lyons RM,Marek BJ,Paley C,Esposito J,McNamara K,Richards PD,DiBella N,Garcia-Manero G

    更新日期：2017-05-01 00:00:00

  • Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide.

    abstract：:We hypothesized that the lipid second messenger, ceramide, and microtubule-directed chemotherapeutic agents might engage converging pathways in inducing apoptosis. Our studies demonstrated that simultaneous treatment of Jurkat cells with paclitaxel and ceramide enhanced paclitaxel-induced cell growth inhibition. Cell ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00048-x

    authors： Myrick D,Blackinton D,Klostergaard J,Kouttab N,Maizel A,Wanebo H,Mehta S

    更新日期：1999-06-01 00:00:00

  • Immunologic cell markers of peripheral blood and lymph node lymphocytes in chronic lymphocytic leukemia.

    abstract：:The immunologic phenotype of the lymphocytes of 100 patients with chronic lymphocytic leukaemia (CLL) was investigated. Peripheral blood lymphocytes (PBL) were examined in all cases; in 46 patients with lymphadenopathy, a lymph node was biopsied and the histologic and immunologic patterns were assessed: 24 had a lymph...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90063-4

    authors： Resegotti L,Palestro G,Novero D,Micca FB,Godio L,Pistone M,Garnero M,Levis A,Stramignoni A

    更新日期：1987-01-01 00:00:00

  • Acid hydrolases in B-chronic lymphocytic leukemia (B-CLL): a comparison with normal peripheral B lymphocytes and normal B-cell subset with the phenotype of B-leukaemic cells.

    abstract：:The acid phosphatase (AP), beta-glucuronidase (BG), and alpha-naphthyl-acetate esterase (ANAE) distribution and the morphology of stage 0 B-CLL lymphocytes were studied. The results were compared with the same hydrolase equipment and morphology of normal B-cell populations showing the B-CLL-like phenotype, and thus re...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90074-9

    authors： Palestro G,Novero D,Godio L,Micca FB,Resegotti L,Stramignon A

    更新日期：1987-01-01 00:00:00

  • miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia.

    abstract：:p23 is a heat shock protein 90 (Hsp90) cochaperone that plays a significant role in estrogen receptor (ER) alpha signal transduction and telomerase activity; it is up-regulated in several cancers. Recent studies have found that high level of p23 may promote tumor progression and poor prognosis in breast cancer patient...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.05.003

    authors： Liu X,Zou L,Zhu L,Zhang H,Du C,Li Z,Gao C,Zhao X,Bao S,Zheng H

    更新日期：2012-09-01 00:00:00